PS T2 is a product-style code, and this review could not independently establish a single authoritative chemical identity for the specific item referenced in the source inventory. That limitation is the central finding. Assigning it a mechanism, clinical effect or approved status without resolving identity would create unsupported information.

Resolve the material before the literature

A research record should identify the full chemical name, sequence where applicable, relevant modifications, salt or counterion, and batch. A code can be useful within one supplier's catalog, but it is not enough to connect the material to a published experiment. Similar abbreviations can also appear in unrelated fields.

FDA's Q7 guidance treats identity, specifications and traceability as distinct quality controls. It illustrates why a label and a certificate must refer to the same defined material rather than merely repeating the same marketing code. FDA Q7 guidance for active pharmaceutical ingredient quality

Do not inherit evidence from a guessed synonym

If a supplier later provides a proposed identity, the relationship should be verified rather than assumed. A matching molecular mass alone may not resolve every structural question. The analytical methods need to be suitable for the specific identification task, a principle reflected in FDA's Q2 guidance. FDA Q2 R2 analytical procedure validation guidance

Only after identity is established can the literature be reviewed for the actual compound. Research on a similarly named substance, an unrelated thyroid metabolite or a different coded product cannot fill the gap. A supplier's explanation remains a supplier claim until supported by appropriate documentation.

AXON can publish an educational discussion of this problem without inventing a PS T2 monograph. This draft is complete as an identity-verification article, but compound-specific chemistry, clinical claims and regulatory conclusions remain unresolved. No sourcing recommendation or administration information is provided. A qualified peptide chemist must resolve the identity before any more specific coverage is drafted.